Stonegate Capital Partners updates coverage on OS Therapies

OS Therapies Incorporated

OS Therapies Incorporated

OSTX

0.00
  • Stonegate Capital Partners updated coverage on OS Therapies, citing increased regulatory visibility for lead candidate OST-HER2 in recurrent, fully resected pulmonary metastatic osteosarcoma.
  • EMA initiated a rolling review for a Conditional Marketing Authorization dossier, while EMA and Australia’s TGA aligned on 3-year overall survival as approvable efficacy endpoint.
  • Focus shifts to upcoming survival readouts, with 2.5-year overall survival data due mid-2Q26 and 3-year data expected early 4Q26 ahead of a potential EMA CMA decision in 4Q26.
  • Funding runway highlighted, including a USD 5.25 million raise and an expected USD 4 million in non-dilutive funding, with a potential priority review voucher cited as additional approval-contingent upside.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202605121435NEWSFILECNPR____20260512_297183_1) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.